Promising Early Results for Ruxolitinib-Decitabine Combination in MPN in Accelerated and Blast Phases
A small, single-arm, phase 2 study results demonstrate efficacy and safety of this combination therapy in patients with MPN-AP or MPN-BP.
A small, single-arm, phase 2 study results demonstrate efficacy and safety of this combination therapy in patients with MPN-AP or MPN-BP.
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.